Enzon Announces CEO Cancer Gold Standard Accreditation.

Company joins elite list of employers dedicated to exceeding workplace wellness standards

BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its CEO Cancer Gold Standard accreditation, an initiative which represents a significant corporate commitment to the health of employees and their families. To attain accreditation, Enzon has exceeded the scope of typical corporate wellness efforts and met the rigorous requirements of the Gold Standard, taking extensive, concrete actions to promote cancer prevention, early detection, and access to quality care.

"As a Company dedicated to the development and commercialization of therapeutics to improve the lives of patients with cancer, Enzon is honored to be recognized by the CEO Cancer Gold Standard," said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon. "We believe that to truly join in the fight against cancer, we must start with our own employees, providing the resources and establishing policies to promote a proactive, health conscious work environment."

Enzon joins other leading healthcare organizations, including AstraZeneca, GlaxoSmithKline, Johnson & Johnson and Novartis, in obtaining the CEO Cancer Gold Standard. To date, Enzon is one of only 12 companies to have earned this accreditation.

The CEO Cancer Gold Standard was developed by the CEO Roundtable on Cancer to assist organizations in reducing the burden of cancer, focusing on five critical areas that help accredited organizations maintain a culture encouraging healthy lifestyles and providing support when a cancer diagnosis is made. The organizations must execute comprehensive programs to reduce employees' tobacco use and improve diet and nutrition, physical activity, use of screenings, and access to quality cancer treatment and clinical trials.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets Abelcet([R]), Oncaspar([R]), Adagen([R]), and Depocyt([R]) in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON([R]), marketed by Schering-Plough Corporation, and MACUGEN([R]), marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology(TM) PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. The Company also engages in contract manufacturing opportunities with third parties to improve its efficiency. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our transition report on Form 10-K for the six-month period ended December 31, 2005 and our quarterly reports on Form 10-Q. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.